Author:
Knauf Wolfgang,Aldaoud Ali,Losem Christoph,Mittermueller Johann,Neise Michael,Niemeier Beate,Harde Johanna,Trarbach Tanja,Potthoff Karin
Funder
iOMEDICO
Celgene International Sàrl (Switzerland)
Subject
Cancer Research,Oncology,Hematology
Reference24 articles.
1. Cancer statistics, 2010;Jemal;CA. Cancer J. Clin.,2010
2. Safety and efficacy of lenalidomide in relapsed or refractory multiple myeloma;Alegre;Clin. Med. Insights Oncol.,2012
3. Lenalidomide in the treatment of multiple myeloma: a review;Armoiry;J. Clin. Pharm. Ther.,2008
4. Thalidomide and lenalidomide: mechanism-based potential drug combinations;Vallet;Leuk. Lymphoma,2008
5. FDA Expands Indication for REVLIMID® (Lenalidomide) in Combination with Dexamethasone to Include Patients Newly Diagnosed with Multiple Myeloma (NASDAQ:CELG), (n.d.). http://ir.celgene.com/releasedetail.cfm?ReleaseID=896912 (Accessed 10 November, 2016).
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献